Takeda’s Uloric: CV Mortality Signal Leads US FDA To Ponder Regulatory Options

Advisory committee will discuss whether CARES postmarketing trial showing 34% increased risk of cardiovascular death for febuxostat warrants market withdrawal, use restrictions, or new labeling for the gout drug.